co-diagnostics - CODX
CODX
Close Chg Chg %
0.32 -0.01 -3.25%
Closed Market
0.31
-0.01 (3.25%)
Volume: 166.48K
Last Updated:
Mar 31, 2025, 4:00 PM EDT
Company Overview: co-diagnostics - CODX
CODX Key Data
| Open $0.31 | Day Range 0.30 - 0.33 |
| 52 Week Range 0.28 - 2.23 | Market Cap $10.22M |
| Shares Outstanding 31.93M | Public Float 29.46M |
| Beta 1.30 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$1.22 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 266.10K |
CODX Performance
| 1 Week | -3.25% | ||
| 1 Month | -37.45% | ||
| 3 Months | -58.72% | ||
| 1 Year | -72.36% | ||
| 5 Years | -96.22% |
CODX Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About co-diagnostics - CODX
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
CODX At a Glance
Co-Diagnostics, Inc.
2401 South Foothill Drive
Salt Lake City, Utah 84109
| Phone | 1-801-438-1036 | Revenue | 770.05K | |
| Industry | Biotechnology | Net Income | -37,639,008.00 | |
| Sector | Health Technology | Employees | 132 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
CODX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 29.546 |
| Price to Book Ratio | 0.456 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.116 |
| Enterprise Value to Sales | -6.29 |
| Total Debt to Enterprise Value | -0.444 |
CODX Efficiency
| Revenue/Employee | 5,833.697 |
| Income Per Employee | -285,144.00 |
| Receivables Turnover | 5.809 |
| Total Asset Turnover | 0.009 |
CODX Liquidity
| Current Ratio | 4.414 |
| Quick Ratio | 4.267 |
| Cash Ratio | 4.066 |
CODX Profitability
| Gross Margin | -208.603 |
| Operating Margin | -5,613.471 |
| Pretax Margin | -4,880.428 |
| Net Margin | -4,887.878 |
| Return on Assets | -43.055 |
| Return on Equity | -53.645 |
| Return on Total Capital | -66.66 |
| Return on Invested Capital | -52.38 |
CODX Capital Structure
| Total Debt to Total Equity | 3.963 |
| Total Debt to Total Capital | 3.812 |
| Total Debt to Total Assets | 3.023 |
| Long-Term Debt to Equity | 2.277 |
| Long-Term Debt to Total Capital | 2.19 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Co-diagnostics - CODX
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 97.89M | 34.22M | 991.47K | 770.05K | |
Sales Growth
| +31.30% | -65.04% | -97.10% | -22.33% | |
Cost of Goods Sold (COGS) incl D&A
| 11.91M | 6.76M | 5.42M | 2.38M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 335.36K | 1.31M | 1.23M | 1.38M | |
Depreciation
| - | - | 335.36K | 1.31M | - |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| -28.81% | -43.21% | -19.94% | -56.12% | |
Gross Income
| 85.98M | 27.45M | (4.42M) | (1.61M) | |
Gross Income Growth
| +48.69% | -68.07% | -116.11% | +63.69% | |
Gross Profit Margin
| +87.83% | +80.23% | -446.20% | -208.60% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 39.76M | 39.05M | 44.10M | 41.62M | |
Research & Development
| 14.96M | 17.44M | 22.96M | 20.98M | |
Other SG&A
| 24.80M | 21.61M | 21.14M | 20.64M | |
SGA Growth
| +146.51% | -1.79% | +12.95% | -5.63% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | 151.00K | 7.49M | - |
EBIT after Unusual Expense
| 46.06M | (19.08M) | (48.53M) | (43.23M) | |
Non Operating Income/Expense
| (429.16K) | 232.96K | 10.42M | 5.64M | |
Non-Operating Interest Income
| 45.63K | 704.04K | 1.16M | 1.09M | |
Equity in Earnings of Affiliates
| (430.43K) | (332.97K) | 100.70K | (186.07K) | |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| 45.64M | (18.85M) | (38.11M) | (37.58M) | |
Pretax Income Growth
| +7.20% | -141.30% | -102.21% | +1.39% | |
Pretax Margin
| +46.62% | -55.08% | -3,843.83% | -4,880.43% | |
Income Tax
| 8.98M | (4.61M) | (2.78M) | 57.37K | |
Income Tax - Current - Domestic
| 6.98M | 297.57K | 6.52M | 8.06M | |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| 2.00M | (4.91M) | (9.30M) | (8.00M) | |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| (430.43K) | (332.97K) | 100.70K | (186.07K) | |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| 36.66M | (14.24M) | (35.33M) | (37.64M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| 36.66M | (14.24M) | (35.33M) | (37.64M) | |
Net Income Growth
| -13.70% | -138.84% | -148.15% | -6.53% | |
Net Margin Growth
| +37.45% | -41.61% | -3,563.67% | -4,887.88% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| 36.66M | (14.24M) | (35.33M) | (37.64M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| 36.66M | (14.24M) | (35.33M) | (37.64M) | |
EPS (Basic)
| 1.2696 | -0.4523 | -1.204 | -1.2408 | |
EPS (Basic) Growth
| -20.14% | -135.63% | -166.20% | -3.06% | |
Basic Shares Outstanding
| 28.87M | 31.48M | 29.35M | 30.34M | |
EPS (Diluted)
| 1.2259 | -0.4523 | -1.204 | -1.2408 | |
EPS (Diluted) Growth
| -19.19% | -136.90% | -166.20% | -3.06% | |
Diluted Shares Outstanding
| 29.90M | 31.48M | 29.35M | 30.34M | |
EBITDA
| 46.55M | (10.28M) | (47.30M) | (41.85M) | |
EBITDA Growth
| +11.28% | -122.08% | -360.16% | +11.52% | |
EBITDA Margin
| +47.56% | -30.04% | -4,770.31% | -5,434.62% |
Snapshot
| Average Recommendation | HOLD | Average Target Price | 1.50 | |
| Number of Ratings | 1 | Current Quarters Estimate | -0.33 | |
| FY Report Date | 06 / 2025 | Current Year's Estimate | -0.91 | |
| Last Quarter’s Earnings | -0.33 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | -1.24 | Next Fiscal Year Estimate | N/A | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | N/A |
| Mean Estimate | -0.33 | -0.21 | -0.91 | N/A |
| High Estimates | -0.33 | -0.21 | -0.91 | N/A |
| Low Estimate | -0.33 | -0.21 | -0.91 | N/A |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 0 | 0 | 0 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 1 | 1 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Hold | Hold | Hold |
SEC Filings for Co-diagnostics - CODX
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Co-diagnostics - CODX
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Nov 26, 2024 | Eugene Durenard Director | 151,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | Richard Abbott President | 150,438 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | Richard Abbott President | 13,915 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $1.01 per share | 14,054.15 |
| Nov 26, 2024 | Richard Abbott President | 20,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Brian L. Brown Chief Financial Officer | 380,833 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | Brian L. Brown Chief Financial Officer | 419,905 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $1.01 per share | 424,104.05 |
| Nov 26, 2024 | Brian L. Brown Chief Financial Officer | 460,721 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Edward L. Murphy Director | 151,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | Edward L. Murphy Director | 175,833 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Richard S. Serbin Director | 165,833 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Eugene Durenard Director | 163,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | James B. Nelson Director | 151,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | James B. Nelson Director | 163,333 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Dwight Howard Egan Chief Executive Officer; Director | 464,167 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| Nov 26, 2024 | Dwight Howard Egan Chief Executive Officer; Director | 522,858 | Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $1.01 per share | 528,086.58 |
| Nov 26, 2024 | Dwight Howard Egan Chief Executive Officer; Director | 572,547 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Nov 26, 2024 | Richard S. Serbin Director | 151,667 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |